Uncategorized

Rhythm Bounces Back from Phase 3 Fail with FDA Nod for Rare Obesity Injection

Published

on

At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version